ISRG vs NVDA: Which Is the Better Buy?

Side-by-side comparison of Intuitive Surgical, Inc. and NVIDIA Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-22.
Intuitive Surgical, Inc. Β· Healthcare
$451.29
+130.4% upside to fair value
Grade B High Quality
VS
NVIDIA Corporation Β· Technology
$182.08
+59.3% upside to fair value
High Conviction Grade A-
QuantHub Verdict
ISRG has more upside to fair value (+130.4%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ISRG NVDA
Current Price $451.29 $182.08
Fair Value Estimate $1,039.74 $290.00
Upside to Fair Value +130.4% +59.3%
Market Cap $160.3B $4,425.5B
Forward P/E 53.8x β€”
EV / EBITDA 40.5x 31.4x
Price / Sales 15.2x 21.0x
Price / FCF 64.3x 46.9x
Revenue Growth YoY +23.0% +65.5%
Gross Margin 66.3% 71.1%
Operating Margin 30.5% 60.4%
Return on Equity 17.0% 76.3%
Dividend Yield 0% 0.02%
FCF Yield 1.55% 2.13%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
ISRG β€” Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a leading healthcare company specializing in robotic-assisted surgery through its flagship da Vinci system, which has established a durable competitive moat with approximately 10,000 systems installed globally and nearly 17 million procedures performed by the end of 2024. The company benefits from a high-quality business model characterized by 85% recurring revenue, st…
NVDA β€” NVIDIA Corporation
NVIDIA is the foundational infrastructure layer of the AI era. Data Center revenue reached $193.7B in FY2026, up 66% YoY, powered by insatiable demand for Blackwell B200 GPUs across hyperscalers and sovereign AI programs. The company generates $96.7B in annual free cash flow with 71% gross margins and 56% net margins, making it the most profitable semiconductor business in history. At P/E 37.7x v…
Accumulation Zones
Metric ISRG NVDA
Zone Low $779.81 $218.00
Zone High $883.78 $250.00
In Buy Zone? Yes Yes
← ISRG Research    NVDA Research β†’    All Research